Auto-populated list of related Clinical Trials
(Breast, Cleft Lip and Palate, Hand, Lymphedema, Oral, Skin, Trauma)

A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors

The purpose of this study is to evaluate the safety and tolerability of study drug, PF-06647020, when given as a single agent at the maximum tolerated dose (MTD) to patients withadvanced non-small cell lung carcinoma (NSCLC), triple negative breast cancer (TNBC) and Ovarian Cancer (OVCA).The preliminary anti-tumor activity of PF-06647020 will also be evaluated and a recommend phase 2 dose (RP2D) will be established.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Pfizer

Intervention(s):

  • Drug: PF-06647020 Q3W
  • Drug: fluconazole
  • Drug: PF-06647020 Q2W
  • Drug: PF-06647020 combined with Avelumab

Phase:

Phase 1

Eligibility


Q2W Inclusion Criteria:

   - Diagnosis of platinum resistant or refractory OVCA having received 2 or fewer prior
   lines, or recurrent advanced NSCLC having received 3 or fewer prior lines

   - Performance Status of 0, 1, or 2

   - Adequate bone marrow, kidney, and liver function

Q2W Exclusion Criteria:

   - OVCA pts excluded with any of the following: non-epithelial, including malignant mixed
   mullerian tumors, unresolved bowel obstruction

   - Brain metastases requiring steroids

   - Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
   study treatment start

   - Active and clinically significant bacterial, fungal, or viral infection

Q3W Inclusion Criteria:

   - Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy
   or for whom no standard therapy is available

   - Performance Status of 0 or 1

   - Adequate bone marrow, kidney, and liver function

   - Part 2 includes ovarian cancer, target expressing triple negative breast cancer and
   non small cell lung cancer patients

Q3W Exclusion Criteria:

   - OVCA pts excluded with any of the following: non-epithelial, including malignant mixed
   mullerian tumors, prior radiotherapy to pelvis/abdomen, pts with CA-125 only disease,
   unresolved bowel obstruction

   - Brain metastases requiring steroids

   - Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
   study treatment start

   - Active and clinically significant bacterial, fungal, or viral infection

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jee Min Lee
650-497-5240
Recruiting

A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors

The purpose of this study is to evaluate the safety and tolerability of study drug, PF-06647020, when given as a single agent at the maximum tolerated dose (MTD) to patients withadvanced non-small cell lung carcinoma (NSCLC), triple negative breast cancer (TNBC) and Ovarian Cancer (OVCA).The preliminary anti-tumor activity of PF-06647020 will also be evaluated and a recommend phase 2 dose (RP2D) will be established.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Pfizer

Intervention(s):

  • Drug: PF-06647020 Q3W
  • Drug: fluconazole
  • Drug: PF-06647020 Q2W
  • Drug: PF-06647020 combined with Avelumab

Phase:

Phase 1

Eligibility


Q2W Inclusion Criteria:

   - Diagnosis of platinum resistant or refractory OVCA having received 2 or fewer prior
   lines, or recurrent advanced NSCLC having received 3 or fewer prior lines

   - Performance Status of 0, 1, or 2

   - Adequate bone marrow, kidney, and liver function

Q2W Exclusion Criteria:

   - OVCA pts excluded with any of the following: non-epithelial, including malignant mixed
   mullerian tumors, unresolved bowel obstruction

   - Brain metastases requiring steroids

   - Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
   study treatment start

   - Active and clinically significant bacterial, fungal, or viral infection

Q3W Inclusion Criteria:

   - Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy
   or for whom no standard therapy is available

   - Performance Status of 0 or 1

   - Adequate bone marrow, kidney, and liver function

   - Part 2 includes ovarian cancer, target expressing triple negative breast cancer and
   non small cell lung cancer patients

Q3W Exclusion Criteria:

   - OVCA pts excluded with any of the following: non-epithelial, including malignant mixed
   mullerian tumors, prior radiotherapy to pelvis/abdomen, pts with CA-125 only disease,
   unresolved bowel obstruction

   - Brain metastases requiring steroids

   - Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
   study treatment start

   - Active and clinically significant bacterial, fungal, or viral infection

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jee Min Lee
650-497-5240
Recruiting

A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors

The purpose of this study is to evaluate the safety and tolerability of study drug, PF-06647020, when given as a single agent at the maximum tolerated dose (MTD) to patients withadvanced non-small cell lung carcinoma (NSCLC), triple negative breast cancer (TNBC) and Ovarian Cancer (OVCA).The preliminary anti-tumor activity of PF-06647020 will also be evaluated and a recommend phase 2 dose (RP2D) will be established.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Pfizer

Intervention(s):

  • Drug: PF-06647020 Q3W
  • Drug: fluconazole
  • Drug: PF-06647020 Q2W
  • Drug: PF-06647020 combined with Avelumab

Phase:

Phase 1

Eligibility


Q2W Inclusion Criteria:

   - Diagnosis of platinum resistant or refractory OVCA having received 2 or fewer prior
   lines, or recurrent advanced NSCLC having received 3 or fewer prior lines

   - Performance Status of 0, 1, or 2

   - Adequate bone marrow, kidney, and liver function

Q2W Exclusion Criteria:

   - OVCA pts excluded with any of the following: non-epithelial, including malignant mixed
   mullerian tumors, unresolved bowel obstruction

   - Brain metastases requiring steroids

   - Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
   study treatment start

   - Active and clinically significant bacterial, fungal, or viral infection

Q3W Inclusion Criteria:

   - Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy
   or for whom no standard therapy is available

   - Performance Status of 0 or 1

   - Adequate bone marrow, kidney, and liver function

   - Part 2 includes ovarian cancer, target expressing triple negative breast cancer and
   non small cell lung cancer patients

Q3W Exclusion Criteria:

   - OVCA pts excluded with any of the following: non-epithelial, including malignant mixed
   mullerian tumors, prior radiotherapy to pelvis/abdomen, pts with CA-125 only disease,
   unresolved bowel obstruction

   - Brain metastases requiring steroids

   - Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
   study treatment start

   - Active and clinically significant bacterial, fungal, or viral infection

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jee Min Lee
650-497-5240
Recruiting

A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors

The purpose of this study is to evaluate the safety and tolerability of study drug, PF-06647020, when given as a single agent at the maximum tolerated dose (MTD) to patients withadvanced non-small cell lung carcinoma (NSCLC), triple negative breast cancer (TNBC) and Ovarian Cancer (OVCA).The preliminary anti-tumor activity of PF-06647020 will also be evaluated and a recommend phase 2 dose (RP2D) will be established.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Pfizer

Intervention(s):

  • Drug: PF-06647020 Q3W
  • Drug: fluconazole
  • Drug: PF-06647020 Q2W
  • Drug: PF-06647020 combined with Avelumab

Phase:

Phase 1

Eligibility


Q2W Inclusion Criteria:

   - Diagnosis of platinum resistant or refractory OVCA having received 2 or fewer prior
   lines, or recurrent advanced NSCLC having received 3 or fewer prior lines

   - Performance Status of 0, 1, or 2

   - Adequate bone marrow, kidney, and liver function

Q2W Exclusion Criteria:

   - OVCA pts excluded with any of the following: non-epithelial, including malignant mixed
   mullerian tumors, unresolved bowel obstruction

   - Brain metastases requiring steroids

   - Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
   study treatment start

   - Active and clinically significant bacterial, fungal, or viral infection

Q3W Inclusion Criteria:

   - Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy
   or for whom no standard therapy is available

   - Performance Status of 0 or 1

   - Adequate bone marrow, kidney, and liver function

   - Part 2 includes ovarian cancer, target expressing triple negative breast cancer and
   non small cell lung cancer patients

Q3W Exclusion Criteria:

   - OVCA pts excluded with any of the following: non-epithelial, including malignant mixed
   mullerian tumors, prior radiotherapy to pelvis/abdomen, pts with CA-125 only disease,
   unresolved bowel obstruction

   - Brain metastases requiring steroids

   - Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
   study treatment start

   - Active and clinically significant bacterial, fungal, or viral infection

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jee Min Lee
650-497-5240
Recruiting

A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors

The purpose of this study is to evaluate the safety and tolerability of study drug, PF-06647020, when given as a single agent at the maximum tolerated dose (MTD) to patients withadvanced non-small cell lung carcinoma (NSCLC), triple negative breast cancer (TNBC) and Ovarian Cancer (OVCA).The preliminary anti-tumor activity of PF-06647020 will also be evaluated and a recommend phase 2 dose (RP2D) will be established.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Pfizer

Intervention(s):

  • Drug: PF-06647020 Q3W
  • Drug: fluconazole
  • Drug: PF-06647020 Q2W
  • Drug: PF-06647020 combined with Avelumab

Phase:

Phase 1

Eligibility


Q2W Inclusion Criteria:

   - Diagnosis of platinum resistant or refractory OVCA having received 2 or fewer prior
   lines, or recurrent advanced NSCLC having received 3 or fewer prior lines

   - Performance Status of 0, 1, or 2

   - Adequate bone marrow, kidney, and liver function

Q2W Exclusion Criteria:

   - OVCA pts excluded with any of the following: non-epithelial, including malignant mixed
   mullerian tumors, unresolved bowel obstruction

   - Brain metastases requiring steroids

   - Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
   study treatment start

   - Active and clinically significant bacterial, fungal, or viral infection

Q3W Inclusion Criteria:

   - Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy
   or for whom no standard therapy is available

   - Performance Status of 0 or 1

   - Adequate bone marrow, kidney, and liver function

   - Part 2 includes ovarian cancer, target expressing triple negative breast cancer and
   non small cell lung cancer patients

Q3W Exclusion Criteria:

   - OVCA pts excluded with any of the following: non-epithelial, including malignant mixed
   mullerian tumors, prior radiotherapy to pelvis/abdomen, pts with CA-125 only disease,
   unresolved bowel obstruction

   - Brain metastases requiring steroids

   - Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
   study treatment start

   - Active and clinically significant bacterial, fungal, or viral infection

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jee Min Lee
650-497-5240
Recruiting

A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors

The purpose of this study is to evaluate the safety and tolerability of study drug, PF-06647020, when given as a single agent at the maximum tolerated dose (MTD) to patients withadvanced non-small cell lung carcinoma (NSCLC), triple negative breast cancer (TNBC) and Ovarian Cancer (OVCA).The preliminary anti-tumor activity of PF-06647020 will also be evaluated and a recommend phase 2 dose (RP2D) will be established.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Pfizer

Intervention(s):

  • Drug: PF-06647020 Q3W
  • Drug: fluconazole
  • Drug: PF-06647020 Q2W
  • Drug: PF-06647020 combined with Avelumab

Phase:

Phase 1

Eligibility


Q2W Inclusion Criteria:

   - Diagnosis of platinum resistant or refractory OVCA having received 2 or fewer prior
   lines, or recurrent advanced NSCLC having received 3 or fewer prior lines

   - Performance Status of 0, 1, or 2

   - Adequate bone marrow, kidney, and liver function

Q2W Exclusion Criteria:

   - OVCA pts excluded with any of the following: non-epithelial, including malignant mixed
   mullerian tumors, unresolved bowel obstruction

   - Brain metastases requiring steroids

   - Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
   study treatment start

   - Active and clinically significant bacterial, fungal, or viral infection

Q3W Inclusion Criteria:

   - Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy
   or for whom no standard therapy is available

   - Performance Status of 0 or 1

   - Adequate bone marrow, kidney, and liver function

   - Part 2 includes ovarian cancer, target expressing triple negative breast cancer and
   non small cell lung cancer patients

Q3W Exclusion Criteria:

   - OVCA pts excluded with any of the following: non-epithelial, including malignant mixed
   mullerian tumors, prior radiotherapy to pelvis/abdomen, pts with CA-125 only disease,
   unresolved bowel obstruction

   - Brain metastases requiring steroids

   - Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
   study treatment start

   - Active and clinically significant bacterial, fungal, or viral infection

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jee Min Lee
650-497-5240
Recruiting

A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors

The purpose of this study is to evaluate the safety and tolerability of study drug, PF-06647020, when given as a single agent at the maximum tolerated dose (MTD) to patients withadvanced non-small cell lung carcinoma (NSCLC), triple negative breast cancer (TNBC) and Ovarian Cancer (OVCA).The preliminary anti-tumor activity of PF-06647020 will also be evaluated and a recommend phase 2 dose (RP2D) will be established.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Pfizer

Intervention(s):

  • Drug: PF-06647020 Q3W
  • Drug: fluconazole
  • Drug: PF-06647020 Q2W
  • Drug: PF-06647020 combined with Avelumab

Phase:

Phase 1

Eligibility


Q2W Inclusion Criteria:

   - Diagnosis of platinum resistant or refractory OVCA having received 2 or fewer prior
   lines, or recurrent advanced NSCLC having received 3 or fewer prior lines

   - Performance Status of 0, 1, or 2

   - Adequate bone marrow, kidney, and liver function

Q2W Exclusion Criteria:

   - OVCA pts excluded with any of the following: non-epithelial, including malignant mixed
   mullerian tumors, unresolved bowel obstruction

   - Brain metastases requiring steroids

   - Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
   study treatment start

   - Active and clinically significant bacterial, fungal, or viral infection

Q3W Inclusion Criteria:

   - Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy
   or for whom no standard therapy is available

   - Performance Status of 0 or 1

   - Adequate bone marrow, kidney, and liver function

   - Part 2 includes ovarian cancer, target expressing triple negative breast cancer and
   non small cell lung cancer patients

Q3W Exclusion Criteria:

   - OVCA pts excluded with any of the following: non-epithelial, including malignant mixed
   mullerian tumors, prior radiotherapy to pelvis/abdomen, pts with CA-125 only disease,
   unresolved bowel obstruction

   - Brain metastases requiring steroids

   - Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
   study treatment start

   - Active and clinically significant bacterial, fungal, or viral infection

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jee Min Lee
650-497-5240
Recruiting

A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors

The purpose of this study is to evaluate the safety and tolerability of study drug, PF-06647020, when given as a single agent at the maximum tolerated dose (MTD) to patients withadvanced non-small cell lung carcinoma (NSCLC), triple negative breast cancer (TNBC) and Ovarian Cancer (OVCA).The preliminary anti-tumor activity of PF-06647020 will also be evaluated and a recommend phase 2 dose (RP2D) will be established.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Pfizer

Intervention(s):

  • Drug: PF-06647020 Q3W
  • Drug: fluconazole
  • Drug: PF-06647020 Q2W
  • Drug: PF-06647020 combined with Avelumab

Phase:

Phase 1

Eligibility


Q2W Inclusion Criteria:

   - Diagnosis of platinum resistant or refractory OVCA having received 2 or fewer prior
   lines, or recurrent advanced NSCLC having received 3 or fewer prior lines

   - Performance Status of 0, 1, or 2

   - Adequate bone marrow, kidney, and liver function

Q2W Exclusion Criteria:

   - OVCA pts excluded with any of the following: non-epithelial, including malignant mixed
   mullerian tumors, unresolved bowel obstruction

   - Brain metastases requiring steroids

   - Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
   study treatment start

   - Active and clinically significant bacterial, fungal, or viral infection

Q3W Inclusion Criteria:

   - Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy
   or for whom no standard therapy is available

   - Performance Status of 0 or 1

   - Adequate bone marrow, kidney, and liver function

   - Part 2 includes ovarian cancer, target expressing triple negative breast cancer and
   non small cell lung cancer patients

Q3W Exclusion Criteria:

   - OVCA pts excluded with any of the following: non-epithelial, including malignant mixed
   mullerian tumors, prior radiotherapy to pelvis/abdomen, pts with CA-125 only disease,
   unresolved bowel obstruction

   - Brain metastases requiring steroids

   - Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
   study treatment start

   - Active and clinically significant bacterial, fungal, or viral infection

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jee Min Lee
650-497-5240
Recruiting

A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors

The purpose of this study is to evaluate the safety and tolerability of study drug, PF-06647020, when given as a single agent at the maximum tolerated dose (MTD) to patients withadvanced non-small cell lung carcinoma (NSCLC), triple negative breast cancer (TNBC) and Ovarian Cancer (OVCA).The preliminary anti-tumor activity of PF-06647020 will also be evaluated and a recommend phase 2 dose (RP2D) will be established.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Pfizer

Intervention(s):

  • Drug: PF-06647020 Q3W
  • Drug: fluconazole
  • Drug: PF-06647020 Q2W
  • Drug: PF-06647020 combined with Avelumab

Phase:

Phase 1

Eligibility


Q2W Inclusion Criteria:

   - Diagnosis of platinum resistant or refractory OVCA having received 2 or fewer prior
   lines, or recurrent advanced NSCLC having received 3 or fewer prior lines

   - Performance Status of 0, 1, or 2

   - Adequate bone marrow, kidney, and liver function

Q2W Exclusion Criteria:

   - OVCA pts excluded with any of the following: non-epithelial, including malignant mixed
   mullerian tumors, unresolved bowel obstruction

   - Brain metastases requiring steroids

   - Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
   study treatment start

   - Active and clinically significant bacterial, fungal, or viral infection

Q3W Inclusion Criteria:

   - Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy
   or for whom no standard therapy is available

   - Performance Status of 0 or 1

   - Adequate bone marrow, kidney, and liver function

   - Part 2 includes ovarian cancer, target expressing triple negative breast cancer and
   non small cell lung cancer patients

Q3W Exclusion Criteria:

   - OVCA pts excluded with any of the following: non-epithelial, including malignant mixed
   mullerian tumors, prior radiotherapy to pelvis/abdomen, pts with CA-125 only disease,
   unresolved bowel obstruction

   - Brain metastases requiring steroids

   - Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
   study treatment start

   - Active and clinically significant bacterial, fungal, or viral infection

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jee Min Lee
650-497-5240
Recruiting

A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors

The purpose of this study is to evaluate the safety and tolerability of study drug, PF-06647020, when given as a single agent at the maximum tolerated dose (MTD) to patients withadvanced non-small cell lung carcinoma (NSCLC), triple negative breast cancer (TNBC) and Ovarian Cancer (OVCA).The preliminary anti-tumor activity of PF-06647020 will also be evaluated and a recommend phase 2 dose (RP2D) will be established.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Pfizer

Intervention(s):

  • Drug: PF-06647020 Q3W
  • Drug: fluconazole
  • Drug: PF-06647020 Q2W
  • Drug: PF-06647020 combined with Avelumab

Phase:

Phase 1

Eligibility


Q2W Inclusion Criteria:

   - Diagnosis of platinum resistant or refractory OVCA having received 2 or fewer prior
   lines, or recurrent advanced NSCLC having received 3 or fewer prior lines

   - Performance Status of 0, 1, or 2

   - Adequate bone marrow, kidney, and liver function

Q2W Exclusion Criteria:

   - OVCA pts excluded with any of the following: non-epithelial, including malignant mixed
   mullerian tumors, unresolved bowel obstruction

   - Brain metastases requiring steroids

   - Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
   study treatment start

   - Active and clinically significant bacterial, fungal, or viral infection

Q3W Inclusion Criteria:

   - Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy
   or for whom no standard therapy is available

   - Performance Status of 0 or 1

   - Adequate bone marrow, kidney, and liver function

   - Part 2 includes ovarian cancer, target expressing triple negative breast cancer and
   non small cell lung cancer patients

Q3W Exclusion Criteria:

   - OVCA pts excluded with any of the following: non-epithelial, including malignant mixed
   mullerian tumors, prior radiotherapy to pelvis/abdomen, pts with CA-125 only disease,
   unresolved bowel obstruction

   - Brain metastases requiring steroids

   - Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
   study treatment start

   - Active and clinically significant bacterial, fungal, or viral infection

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jee Min Lee
650-497-5240
Recruiting

A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors

The purpose of this study is to evaluate the safety and tolerability of study drug, PF-06647020, when given as a single agent at the maximum tolerated dose (MTD) to patients withadvanced non-small cell lung carcinoma (NSCLC), triple negative breast cancer (TNBC) and Ovarian Cancer (OVCA).The preliminary anti-tumor activity of PF-06647020 will also be evaluated and a recommend phase 2 dose (RP2D) will be established.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Pfizer

Intervention(s):

  • Drug: PF-06647020 Q3W
  • Drug: fluconazole
  • Drug: PF-06647020 Q2W
  • Drug: PF-06647020 combined with Avelumab

Phase:

Phase 1

Eligibility


Q2W Inclusion Criteria:

   - Diagnosis of platinum resistant or refractory OVCA having received 2 or fewer prior
   lines, or recurrent advanced NSCLC having received 3 or fewer prior lines

   - Performance Status of 0, 1, or 2

   - Adequate bone marrow, kidney, and liver function

Q2W Exclusion Criteria:

   - OVCA pts excluded with any of the following: non-epithelial, including malignant mixed
   mullerian tumors, unresolved bowel obstruction

   - Brain metastases requiring steroids

   - Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
   study treatment start

   - Active and clinically significant bacterial, fungal, or viral infection

Q3W Inclusion Criteria:

   - Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy
   or for whom no standard therapy is available

   - Performance Status of 0 or 1

   - Adequate bone marrow, kidney, and liver function

   - Part 2 includes ovarian cancer, target expressing triple negative breast cancer and
   non small cell lung cancer patients

Q3W Exclusion Criteria:

   - OVCA pts excluded with any of the following: non-epithelial, including malignant mixed
   mullerian tumors, prior radiotherapy to pelvis/abdomen, pts with CA-125 only disease,
   unresolved bowel obstruction

   - Brain metastases requiring steroids

   - Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
   study treatment start

   - Active and clinically significant bacterial, fungal, or viral infection

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jee Min Lee
650-497-5240
Recruiting

A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors

The purpose of this study is to evaluate the safety and tolerability of study drug, PF-06647020, when given as a single agent at the maximum tolerated dose (MTD) to patients withadvanced non-small cell lung carcinoma (NSCLC), triple negative breast cancer (TNBC) and Ovarian Cancer (OVCA).The preliminary anti-tumor activity of PF-06647020 will also be evaluated and a recommend phase 2 dose (RP2D) will be established.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Pfizer

Intervention(s):

  • Drug: PF-06647020 Q3W
  • Drug: fluconazole
  • Drug: PF-06647020 Q2W
  • Drug: PF-06647020 combined with Avelumab

Phase:

Phase 1

Eligibility


Q2W Inclusion Criteria:

   - Diagnosis of platinum resistant or refractory OVCA having received 2 or fewer prior
   lines, or recurrent advanced NSCLC having received 3 or fewer prior lines

   - Performance Status of 0, 1, or 2

   - Adequate bone marrow, kidney, and liver function

Q2W Exclusion Criteria:

   - OVCA pts excluded with any of the following: non-epithelial, including malignant mixed
   mullerian tumors, unresolved bowel obstruction

   - Brain metastases requiring steroids

   - Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
   study treatment start

   - Active and clinically significant bacterial, fungal, or viral infection

Q3W Inclusion Criteria:

   - Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy
   or for whom no standard therapy is available

   - Performance Status of 0 or 1

   - Adequate bone marrow, kidney, and liver function

   - Part 2 includes ovarian cancer, target expressing triple negative breast cancer and
   non small cell lung cancer patients

Q3W Exclusion Criteria:

   - OVCA pts excluded with any of the following: non-epithelial, including malignant mixed
   mullerian tumors, prior radiotherapy to pelvis/abdomen, pts with CA-125 only disease,
   unresolved bowel obstruction

   - Brain metastases requiring steroids

   - Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
   study treatment start

   - Active and clinically significant bacterial, fungal, or viral infection

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jee Min Lee
650-497-5240
Recruiting